{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=45", "query": { "condition": "Phase 2 Study", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 17257, "total_pages": 1726, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+2+Study&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T23:40:31.510Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03420521", "title": "Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Carcinoid Tumor" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 9, "start_date": "2018-03-09", "completion_date": "2021-11-24", "has_results": true, "last_update_posted_date": "2024-01-09", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03420521" }, { "nct_id": "NCT00787267", "title": "Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2008-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 3, "location_summary": "Durham, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787267" }, { "nct_id": "NCT03580928", "title": "Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "Venetoclax", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Acalabrutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 72, "start_date": "2018-08-07", "completion_date": "2027-12-31", "has_results": true, "last_update_posted_date": "2026-02-13", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 4, "location_summary": "Stamford, Connecticut • Boston, Massachusetts • Providence, Rhode Island", "locations": [ { "city": "Stamford", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03580928" }, { "nct_id": "NCT01257230", "title": "Efficacy and Safety of 2 Doses of Tiotropium Via Respimat Compared to Placebo in Adolescents With Moderate Persistent Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "tiotropium Respimat low dose", "type": "DRUG" }, { "name": "placebo Respimat", "type": "DRUG" }, { "name": "tiotropium Respimat high dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 398, "start_date": "2010-12", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2014-09-05", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 8, "location_summary": "Plymouth, Minnesota • Columbia, Missouri • Cincinnati, Ohio + 4 more", "locations": [ { "city": "Plymouth", "state": "Minnesota" }, { "city": "Columbia", "state": "Missouri" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Oklahoma City", "state": "Oklahoma" }, { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01257230" }, { "nct_id": "NCT00315211", "title": "Weekly Topotecan With Docetaxel in Recurrent Small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mediastinal Neoplasms" ], "interventions": [ { "name": "Intravenous Topotecan", "type": "DRUG" }, { "name": "Intravenous Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aultman Health Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2004-11", "completion_date": "2007-11-08", "has_results": false, "last_update_posted_date": "2018-08-20", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 1, "location_summary": "Canton, Ohio", "locations": [ { "city": "Canton", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00315211" }, { "nct_id": "NCT04535544", "title": "A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis D, Chronic" ], "interventions": [ { "name": "JNJ-73763989", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Entecavir (ETV) monohydrate", "type": "DRUG" }, { "name": "Tenofovir disoproxil", "type": "DRUG" }, { "name": "Tenofovir alafenamide (TAF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 52, "start_date": "2020-09-17", "completion_date": "2025-03-05", "has_results": true, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 2, "location_summary": "Redwood City, California • Boston, Massachusetts", "locations": [ { "city": "Redwood City", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04535544" }, { "nct_id": "NCT03446144", "title": "Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Geographic Atrophy", "Age Related Macular Degeneration" ], "interventions": [ { "name": "IONIS-FB-Lrx", "type": "DRUG" }, { "name": "Placebo (sterline saline 0.9%)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ionis Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 0, "start_date": "2018-03-16", "completion_date": "2018-10-10", "has_results": false, "last_update_posted_date": "2019-08-13", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 24, "location_summary": "Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446144" }, { "nct_id": "NCT01667536", "title": "A Phase 2 Study With MIP-1404 in Men With High-Risk PC Scheduled for RP and EPLND Compared to Histopathology", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Drug: 99mTc-MIP-1404", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Insight Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "MALE", "summary": "21 Years and older · Male only" }, "enrollment_count": 105, "start_date": "2012-08", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2017-02-07", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 10, "location_summary": "Duarte, California • Rochester, Minnesota • New York, New York + 7 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01667536" }, { "nct_id": "NCT06827236", "title": "A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Breast Cancer", "Unresectable Breast Carcinoma", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BNT323", "type": "DRUG" }, { "name": "BNT327", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2025-04-23", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 28, "location_summary": "Beverly Hills, California • Newport Beach, California • Port Saint Lucie, Florida + 18 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06827236" }, { "nct_id": "NCT00879034", "title": "A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Progeria", "Hutchinson-Gilford Syndrome" ], "interventions": [ { "name": "Lonafarnib", "type": "DRUG" }, { "name": "Zoledronic Acid", "type": "DRUG" }, { "name": "Pravastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boston Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "2009-03", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2019-06-13", "last_synced_at": "2026-10-24T23:40:31.510Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00879034" } ] }